Intermediate-term results with 1,019 carbomedics aortic valves

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science
• Clinical Outcomes Research

Background:

• Evaluation of prosthetic heart valves is crucial for improving patient outcomes.
• The Carbomedics aortic valve prosthesis is a mechanical device used in valve replacement surgery.

Purpose of the Study:

• To assess the intermediate-term clinical performance and safety of the Carbomedics aortic valve prosthesis.
• To identify risk factors associated with mortality and complications in patients receiving this prosthesis.

Main Methods:

• Retrospective analysis of 1,019 primary aortic valve replacements performed between 1989 and 1997.
• Long-term follow-up (mean 2.7 years, up to 9 years) with 99.6% completeness.
• Statistical analysis to determine survival rates and linearized event rates.

Main Results:

• Seven-year patient survival was 80%, with a linearized death rate of 2.9%/year.
• Significant mortality risk factors included diabetes, valve insufficiency, advanced age, and functional class.
• Low linearized complication rates: thrombosis (0.1%), thromboembolism (1.0%), hemorrhage (1.7%), endocarditis (0.1%), paravalvular leak (0.1%), reoperation (0.1%).
• Seven-year freedom from all events was 82%; no structural valve failure observed.

Conclusions:

• The Carbomedics aortic valve prosthesis demonstrates favorable intermediate-term outcomes.
• Low rates of valve-related complications support its continued use in the aortic position.